Abivax SA (ABVX)
Abivax SA (ABVX) surges towards a 52-week high, fueled by strong clinical trial results for obefazimod and increasing M&A speculation. Social media buzz highlights potential buyouts and drug efficacy.
About Abivax SA
Abivax SA is a clinical-stage biotechnology company focused on developing novel small molecule drugs for inflammatory and fibrotic diseases.
Abivax SA uses the ticker $ABVX for trading. Listed in the Stocks category.
Insights
- Abivax SA (ABVX) market dominance near a 52-week high at [-------].
- Abivax SA (ABVX) sentiment is up 19.4% from the previous week.
- Abivax SA (ABVX) creators is up 13.32% from the previous week.
- Abivax SA (ABVX) engagements is up 60.68% from the previous week.
- Abivax SA (ABVX) mentions is up 31.02% from the previous week.
- Abivax SA (ABVX) posts created is up 129.93% from the previous week.
- Abivax SA Price hit a 52-Week high of $125.60 for the hour
- Abivax SA Price hit an all time of $125.60 for the hour
Price: $125
Price 24-Hour Time-Series Raw Data
The stock price is likely reacting positively to strong clinical trial results and ongoing M&A speculation, indicating investor confidence in the drug's potential and a possible acquisition. Recent social media posts echo this sentiment, with many discussing potential buyouts and the drug's efficacy.
24-Hour: 0.79% 7-Day: 4.35% 30-Day: 6.74%
1-Year High: $145.30 on 2025-12-24
1-Year Low: $6 on 2025-06-20
AltRank: [---]
AltRank 24-Hour Time-Series Raw Data
Abivax SA (ABVX) is currently AltRank #235 based on combined combined social and market metrics
Daily Average: [---]
[--] Week: [---] [---]
1-Year High: [---] on 2026-02-09
1-Year Low: [--] on 2026-01-25
Galaxy Score: [-----]
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] [---]
1-Year High: [--] on 2026-01-26
1-Year Low: [--] on 2026-01-24
Engagements: [------] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [------]
Daily Average: [------]
[--] Week: [-------] +61%
[--] Month: [---------] -61%
[--] Months: [----------] +220%
[--] Year: [----------] +2,787%
1-Year High: [---------] on 2025-07-23
1-Year Low: [--] on 2025-05-10
Engagements by network (24h): Reddit: [--] News: [--] X: [------] TikTok: [--] YouTube: [--]
Mentions: [---] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [---]
Daily Average: [---]
[--] Week: [-----] +31%
1-Year High: [-----] on 2025-07-24
1-Year Low: [--] on 2025-05-10
Mentions by network (24h): Reddit: [--] News: [--] X: [---] TikTok: [--] YouTube: [--]
Creators: [---] (24h)
Creators 24-Hour Time-Series Raw Data
[---] unique social accounts have posts mentioning Abivax SA (ABVX) in the last [--] hours which is down 32% from [---] in the previous [--] hours
Daily Average: [---]
[--] Week: [---] +13%
1-Year High: [---] on 2025-07-24
1-Year Low: [--] on 2025-05-10
The most influential creators that mention Abivax SA in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @biotechbeta | [--] | [---] | [--] | [------] |
| @Agent0088156721 | [--] | [---] | [--] | [-----] |
| @Taintslapp12283 | [--] | [---] | [--] | [-----] |
| @DSAkdag | [--] | [------] | [--] | [-----] |
| @biotech_jack | [--] | [---] | [--] | [-----] |
| @tradingsssss | [--] | [-----] | [--] | [-----] |
| @seedy19tron | [--] | [------] | [--] | [-----] |
| @AponiaAnalytics | [--] | [-----] | [--] | [-----] |
| @SizeInvestor | [--] | [--] | [--] | [-----] |
| @MACROVET888 | [--] | [---] | [--] | [---] |
Sentiment: 69%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 69%
Daily Average: 84%
[--] Week: 80% +13%
[--] Month: 65% -6%
[--] Months: 65% -23%
[--] Year: 65% -35%
1-Year High: 100% on 2025-02-26
1-Year Low: 50% on 2025-02-20
Most Supportive Themes:
- Positive Trial Results: (60%) Abivax announced positive results from its Phase 2b clinical trial for obefazimod in ulcerative colitis patients. The drug demonstrated significant efficacy and a favorable safety profile.
- Regulatory Progress: (30%) The company is actively engaging with regulatory authorities, including the FDA and EMA, to advance obefazimod towards market approval. Discussions are ongoing regarding the next steps in the regulatory process.
Most Critical Themes:
- Competition in IBD Market: (7.5%) The inflammatory bowel disease (IBD) market is highly competitive, with several established and emerging therapies. Abivax's obefazimod will face significant competition from existing treatments and new entrants.
- Manufacturing Scale-Up Challenges: (2.5%) Scaling up manufacturing for a new pharmaceutical product can present challenges. Ensuring consistent quality and sufficient supply to meet potential market demand will be crucial for Abivax.
Social Dominance: 0.019%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.019%
Daily Average: 0.028%
[--] Week: 0.039% +0.0005000000000000004%
[--] Month: 0.022% -0.057%
[--] Months: 0.022% -0.016%
[--] Year: 0.022% +0.019%
1-Year High: 0.184% on 2025-07-24
1-Year Low: 0.0004% on 2025-05-10
Market Dominance: 0.011%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.011%
Daily Average: 0%
1-Year High: 0.012% on 2026-02-15
1-Year Low: 0.01% on 2026-02-02
Market Cap: $9,905,428,110
Market Cap 24-Hour Time-Series Raw Data
Current Value: $9,905,428,110
Daily Average: $9,340,466,719
[--] Week: $9,905,428,110 +5.30%
[--] Month: $9,883,287,774 +7.60%
1-Year High: $9,883,287,774 on 2026-02-13
1-Year Low: $8,754,130,646 on 2026-02-05
Top Abivax SA Social Posts
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"$ABVX (1/n) $ABVX ECCO Abstract #1 https://t.co/6ZArcusNEF (1/n) $ABVX ECCO Abstract #1 https://t.co/6ZArcusNEF"
X Link @AponiaAnalytics 2026-02-16T21:35Z [----] followers, [---] engagements
"$ABVX Getting warmer. A discreet search. A discreet hire (no company pr re a Sr hire). Hire has extensive experience incl critical NDA exp. The whole value proposition is predicated on a FDA NDA getting file this year with EMA MAA poss going parallel. The hire derisks imo"
X Link @Agent0088156721 2026-02-16T17:54Z [---] followers, [----] engagements
"(24/n) $ABVX TAKEAWAYS [--]. reframing obe as more than an anti-inflammatory. the fibrosis abstract is HUGE - If miR-124 modulation shows anti-fibrotic signal in IBD models theyre hinting at disease mod. In Crohns especially fibrosis = unmet need + surgical burden = higherSP"
X Link @biotechbeta 2026-02-16T17:38Z [---] followers, [----] engagements
"$azn $pfe $jnj $nvs $bmy $gsk $abbv $mrk $sny #biotech #pharma #cancer $nvo $lly $xbi $amgn $rhhby $aapl $tsla $abvx $rvmd $sgmo 1/🚨 This short and excellent FT article tells the tale of AstraZenecas huge success story and how $AZN is paving its way towards fulfilling its ambitious corporate goal of $80B in revenue by [----]. This massive achievement is based mainly on a fantastic track record of [--] https://t.co/WfYnmDHjTV 1/🚨 This short and excellent FT article tells the tale of AstraZenecas huge success story and how $AZN is paving its way towards fulfilling its ambitious corporate goal of"
X Link @HalevyMike 2026-02-16T15:56Z [----] followers, [---] engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing